Pilot study of levosimendan: Effect on liver blood flow and liver function in acute decompensated heart failure;Pilotstudie zu Levosimendan: Effekt auf Leberdurchblutung und -funktion bei akut dekompensierter Herzinsuffizienz

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Volumn 109, Issue 4, 2014, Pages 267-270

  Lenz, K ^a   Gegenhuber, A ^b   Firlinger, F ^a   Lohr, G ^a   Piringer, P ^a  

^a Konvent Hospital Barmherzige Brüder Linz   (Austria)

^b Interne Abteilung Landeskrankenhaus Bad Ischl   (Austria)

Author keywords

Cardiomyopathies; Clinical trial; Hemodynamics; Indocyangreen plasma disappearance rate; Intensive care

Indexed keywords

INDOCYANINE GREEN; LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ADULT; ARTICLE; BLOOD FLOWMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; HEART INDEX; HUMAN; LIVER BLOOD FLOW; LIVER FUNCTION; LIVER FUNCTION TEST KIT; PILOT STUDY; PLASMA CLEARANCE; AGED; BLOOD FLOW; CARDIAC OUTPUT, LOW; DIAGNOSTIC USE; DRUG EFFECTS; FEMALE; HEART FAILURE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER FAILURE; LIVER FUNCTION TEST; MALE; MIDDLE AGED; VASCULARIZATION;

ADULT; AGED; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; HYDRAZONES; INDOCYANINE GREEN; INFUSIONS, INTRAVENOUS; LIVER; LIVER FAILURE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRIDAZINES; REGIONAL BLOOD FLOW;

EID: 84901194441     PISSN: 21936218     EISSN: 21936226     Source Type: Journal    
DOI: 10.1007/s00063-013-0326-z     Document Type: Article

References (19)

1. Nicolaou M, Parissis J, Yilmaz MB et al (2013) Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 34: 742-749.
2. Ambrosy AP, Vaduganathan M, Huffman MD et al (2012) Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 14: 302-311.
3. Krum H, Teerlink JR (2011) Medical therapy for chronic heart failure. Lancet 378: 713-721.
4. Landoni G, Biondi-Zoccai G, Greco M et al (2012) Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controller studies. Crit Care Med 40: 634-646.
5. Leier CV, Heban PT, Huss P et al (1978) Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 58: 466-475.
6. Pagel PS, Hettrick DA, Waritier DC (1996) Influence of levosimendan, pimendan, and milrinone on the regional distribution of cardiac output in anaesthezid dog. Br J Pharmacol 119: 609-615.
7. Thümer O, Hüttemann E, Salla SG (2007) Indozyaningrün - Plasmaverschwinde-rate - Marker einer partiellen Ischämie im Hepatosplanchnikusktrakt. Anästhesist 56: 339-344.
8. Fuhrmann V, Kneidinger N, Herkner H et al (2009) Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 35: 1397-1405.
9. Myers JO, Hickmann JB (1948) An estimation of the hepatic blood flow and splachnic oxygen consumption in heart failure. J Clin Invest 27: 620-627.
10. Plenz G, Song ZF, Tjan TD et al (2001) Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 3: 415-421.
11. Geppart A, Steiner A, Zorn G et al (2002) Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin 6. Crit Care Med 30: 1987-1994.
12. Avgeropoulou C, Andreadou I, Markantonis-Kyroiudis S et al (2005) The Ca sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7: 882-887.
13. Memis D, Inal MT, Sut N (2012) The effect of levosimendan vs dobutamin added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. J Crit Care 27: 318. e1-e6.
14. Pasqui AL, Maffei S, DiRenzo M et al (2011) Levosimendan improve por/anti-inflammatory cytokines ambalance in male patients with advanced heart failure. A randomized, double blind, placebo controlled study. Int J Cardiol 147: 314-315.
15. Gornikiewicz A, Sautner T, Brostjan C et al (2000) Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. FASEB J 14: 1093-1100.
16. Trikas A, Antoniades C, Latsios G et al (2006) Long term effect of levosimendan infusion on inflammatoriy processes and sFas in patients with severe heart failure. Eur J Heart Fail 8: 804-809.
17. Parissis JT, Adamopoulos S, Antoniades C et al (2004) Effects of levosimedan on circulation pro inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93: 1309-1312.
18. Nesseler N, Launey Y, Aninant C et al (2012) Clinical review: the liver in sepsis. Crit Care 16: 235.
19. Lenz K (2006) Leberversagen bei Sepsis und Multiorganversagen. Intensivmed 43: 29-36.